Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 28, 2015; 21(12): 3571-3578
Published online Mar 28, 2015. doi: 10.3748/wjg.v21.i12.3571
Published online Mar 28, 2015. doi: 10.3748/wjg.v21.i12.3571
Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms
Gabriele Stocco, Giuliana Decorti, Department of Life Sciences, University of Trieste, I-34127 Trieste, Italy
Eva Cuzzoni, PhD School in Sciences of Reproduction and Development, University of Trieste, I-34127 Trieste, Italy
Alessandro Ventura, Department of Medical, Surgical and Health Sciences, University of Trieste, I-34127 Trieste, Italy
Sara De Iudicibus, Diego Favretto, Stefano Martelossi, Alessandro Ventura, Institute for Maternal and Child Health IRCCS Burlo Garofolo, I-34127 Trieste, Italy
Noelia Malusà, Department of Prevention, Sanitary Services Agency Number 1, I-34127 Trieste, Italy
Elena Pozzi, Paolo Lionetti, Research Children’s Hospital “Meyer”, I-50139 Florence, Italy
Author contributions: Stocco G, Martelossi M, Ventura A and Decorti G designed the study; Martelossi S, Lionetti P, Pozzi E and Ventura A enrolled the patients; Cuzzoni E, De Iudicibus S, Favretto D and Malusà N genotyped samples and performed the high performance liquid chromatography analyses; Stocco G, Cuzzoni E, De Iudicibus S and Decorti G wrote the paper; all authors critically discussed the results.
Supported by Italian Ministry of Health, and Fondazione Benefica Alberto e Kathleen Casali.
Ethics approval: The study was reviewed and approved by the Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo Medical Etics Review Board, approval Trieste (n. 58/05, 12/12/2005) and by the Institutional Research Board (#23/05).
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: All authors declare they have no conflict of interest.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Giuliana Decorti, MD, Professor, Department of Life Sciences, University of Trieste, via Fleming 22, I-34127 Trieste, Italy. decorti@units.it
Telephone: +39-40-5588777 Fax: +39-40-5582134
Received: October 1, 2014
Peer-review started: October 3, 2014
First decision: October 29, 2014
Revised: November 23, 2014
Accepted: January 16, 2015
Article in press: January 16, 2015
Published online: March 28, 2015
Peer-review started: October 3, 2014
First decision: October 29, 2014
Revised: November 23, 2014
Accepted: January 16, 2015
Article in press: January 16, 2015
Published online: March 28, 2015
Core Tip
Core tip: During treatment of inflammatory bowel disease with thiopurines and aminosalicylates, interruption of the aminosalicylate results in a significant decrease in thiopurines’ thioguanine nucleotides (TGN) active metabolites. Genetic polymorphisms in genes involved in aminosalicylates biotransformation (NAT1 genotype) affects TGN levels in patients treated with thiopurines and aminosalicylates and could therefore influence the toxicity and efficacy of these drugs.